Search | IOVS | ARVO Journals

Showing 1 – 19 of 19

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Letters to the Editor October 2023

Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME

PDF

Robert L. Avery; Karl G. Csaky; Peter Westenskow; Ivaylo Stoilov; Cheikh Diack
TAGS: aflibercept, angiopoietins
Trans. Vis. Sci. Tech.. 2023; 12(10):6. https://doi.org/10.1167/tvst.12.10.6

ARVO Annual Meeting Abstract June 2023

An assessment of the impact of disease activity criteria on dosing interval assignment in clinical trial patients with nAMD

Marco A Zarbin; Christina Weng; Audrey Souverain; Ivaylo Stoilov; philippe margaron

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2181.

ARVO Annual Meeting Abstract July 2019

Pigment Epithelial Detachments Response to a Single Ranibizumab Injection: a HARBOR Subanalysis

Michael Javaheri; Lauren Hill; Avanti Ghanekar; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):75.

ARVO Annual Meeting Abstract July 2019

Trends for poorer vision outcomes in nAMD and DME patients with higher aqueous humor levels of IL-6

Yasir Jamal Sepah; Quan Dong Nguyen; Diana V Do; Bann-mo Day; Eric Wakshull; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4938.

ARVO Annual Meeting Abstract July 2019

Patients ultra-responsive to ranibizumab: rates of ≥4-step improvement in diabetic retinopathy severity in DRCR.net Protocol S

Michael A. Klufas; Allen Chiang; Lauren Hill; Min Tsuboi; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5358.

ARVO Annual Meeting Abstract July 2019

Identifying Factors Associated with Blindness in Patients with Diabetic Retinopathy: Insights from the AAO IRIS® Registry

Charles Clifton Wykoff; Rebecca Hall; Scott Kelly; Flora Lum; Ivaylo Stoilov; Ibrahim Abbass; Tu-My To; Anna M Abolian; Vincent Garmo

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1090.

ARVO Annual Meeting Abstract July 2019

Effect of external surface terminal sterilization of prefilled syringes (PFS) with ethylene oxide (EO) on the concentration and stability of ranibizumab (RBZ)

Nikolas London; Shrirang Ranade; Ivaylo Stoilov; Jasper Lin; Mayumi Bowen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3349.

ARVO Annual Meeting Abstract July 2018

Baseline factors associated with ≥ 2-step diabetic retinopathy (DR) severity improvement with ranibizumab (RBZ)

Dilsher Dhoot; Lauren Hill; Kathleen Tarnowski; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3592.

ARVO Annual Meeting Abstract July 2018

Baseline characteristics associated with good visual acuity outcomes in myopic choroidal neovascularization: results from the RADIANCE trial

Carolyn Pan; Diana V Do; Lauren Hill; Tatiana Ecoiffier; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):783.

ARVO Annual Meeting Abstract July 2018

Association Between Timing of Peak Vision Gain and Long-Term Outcomes of Ranibizumab for nAMD: A Post Hoc Analysis of HARBOR

Louis Chang; Rahul N. Khurana; Bann-mo Day; Avanti Ghanekar; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):836.

ARVO Annual Meeting Abstract July 2018

Analysis of the serum and aqueous humor levels of IL-6 in patients with neovascular (wet) age-related macular degeneration (nAMD) receiving anti-vascular endothelial growth factor A monotherapy

Eric Wakshull; Kyu Hong; Bann-mo Day; Min Bao; Hugh Lin; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1456.

ARVO Annual Meeting Abstract September 2016

The top 10 findings from the RIDE/RISE trials of ranibizumab in patients with diabetic macular edema

Rishi P Singh; Lisa Tuomi; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract June 2015

Ranibizumab for DME following laser and/or steroid treatments: a RIDE/RISE subanalysis

Sara J. Haug; Beiying Ding; Na Lu; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1759.

ARVO Annual Meeting Abstract June 2015

Diabetic macular edema outcomes with anti-VEGF treatments: comparison of randomized controlled clinical studies

Geeta Lalchandani; Na Lu; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1766.

ARVO Annual Meeting Abstract June 2015

Diabetic retinopathy outcomes with anti-VEGF treatments: clinical experience in randomized clinical trials

Dante Joseph Pieramici; Na Lu; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1775.

ARVO Annual Meeting Abstract June 2015

Long-term improvements in vision and diabetic retinopathy achieved and maintained with PRN ranibizumab therapy in the RIDE and RISE trials

Michael J Elman; Jiameng Zhang; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3145.

ARVO Annual Meeting Abstract June 2015

Low luminance vision improves nearly twice as much as standard vision with ranibizumab for neovascular age-related macular degeneration

Ronald E P Frenkel; Anne E. Fung; Howard Shapiro; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5358.

ARVO Annual Meeting Abstract June 2015

Visual acuity impairment under low luminance conditions at baseline is a powerful predictor of visual acuity response to ranibizumab therapy in patients with neovascular age-related macular degeneration

Marc C. Peden; Ronald E P Frenkel; Howard Shapiro; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5362.

Glaucoma June 2002

Molecular Genetics of Primary Congenital Glaucoma in Brazil

PDF

Ivaylo R. Stoilov; Vital P. Costa; Jose P. C. Vasconcellos; Monica B. Melo; Alberto J. Betinjane; Jose C. E. Carani; Ernst V. Oltrogge; Mansoor Sarfarazi
TAGS: brazil, genetics, molecular, glaucoma, congenital, mutation, single nucleotide polymorphism, dna, haplotypes, screening, polymorphism, single-stranded conformational
Invest. Ophthalmol. Vis. Sci.. 2002; 43(6):1820-1827.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME

An assessment of the impact of disease activity criteria on dosing interval assignment in clinical trial patients with nAMD

Pigment Epithelial Detachments Response to a Single Ranibizumab Injection: a HARBOR Subanalysis

Trends for poorer vision outcomes in nAMD and DME patients with higher aqueous humor levels of IL-6

Patients ultra-responsive to ranibizumab: rates of ≥4-step improvement in diabetic retinopathy severity in DRCR.net Protocol S

Identifying Factors Associated with Blindness in Patients with Diabetic Retinopathy: Insights from the AAO IRIS® Registry

Effect of external surface terminal sterilization of prefilled syringes (PFS) with ethylene oxide (EO) on the concentration and stability of ranibizumab (RBZ)

Baseline factors associated with ≥ 2-step diabetic retinopathy (DR) severity improvement with ranibizumab (RBZ)

Baseline characteristics associated with good visual acuity outcomes in myopic choroidal neovascularization: results from the RADIANCE trial

Association Between Timing of Peak Vision Gain and Long-Term Outcomes of Ranibizumab for nAMD: A Post Hoc Analysis of HARBOR

Analysis of the serum and aqueous humor levels of IL-6 in patients with neovascular (wet) age-related macular degeneration (nAMD) receiving anti-vascular endothelial growth factor A monotherapy

The top 10 findings from the RIDE/RISE trials of ranibizumab in patients with diabetic macular edema

Ranibizumab for DME following laser and/or steroid treatments: a RIDE/RISE subanalysis

Diabetic macular edema outcomes with anti-VEGF treatments: comparison of randomized controlled clinical studies

Diabetic retinopathy outcomes with anti-VEGF treatments: clinical experience in randomized clinical trials

Long-term improvements in vision and diabetic retinopathy achieved and maintained with PRN ranibizumab therapy in the RIDE and RISE trials

Low luminance vision improves nearly twice as much as standard vision with ranibizumab for neovascular age-related macular degeneration

Visual acuity impairment under low luminance conditions at baseline is a powerful predictor of visual acuity response to ranibizumab therapy in patients with neovascular age-related macular degeneration

Molecular Genetics of Primary Congenital Glaucoma in Brazil

To View More...

You must be signed into an individual account to use this feature.